No Data
Rayon Genomics 2024 annual results forecast
Ruian Gene (688217.SH): It is expected that the net loss in 2024 will be between 11.2943 million yuan and 16.9415 million yuan.
Gelonghui, January 17th丨Ruiong Gene (688217.SH) announced that, 1. According to preliminary estimates by the finance department, the company expects to achieve revenue of 238 million yuan to 245 million yuan in 2024, which is a year-on-year decrease of 5.12% to 7.83% compared to the same period last year (statutory disclosed data). 2. The company expects to realize a net income attributed to shareholders of the parent company to be between -11.2943 million yuan and -16.9415 million yuan in 2024, indicating a loss compared to the same period last year. 3. The company expects to achieve a net income attributed to shareholders of the parent company after deductions in 2024.
Ruian Gene (688217.SH): Plans to sign a "Public Rental Housing First Rent Then Sell Contract" with related parties.
On January 10, Gelonghui reported that Ruiang Gene (688217.SH) announced that the company plans to sign a "Public Rental Housing Lease Purchase Agreement" with related parties Gao Shangxian, Li Yunhang, Sun Yanbo, and Zhang Chengli (hereinafter referred to as "the above-mentioned related parties"). The above-mentioned related parties intend to rent and purchase some properties at No. 19, Lane 1288, Guangfeng Road, Fengxian District, Shanghai (Guangfeng Mingdu) for residential use. The building area of the houses to be rented and purchased by Gao Shangxian, Li Yunhang, Sun Yanbo, and Zhang Chengli is 101.98 square meters each, with a lease term of 10 years. The total amount of the four contracts is approximately 9.5806 million yuan (among which
Express News | Shanghai Rightongene Says Co's Business Activities Remain Normal; Matter Will Not Have Adverse Impact on Co's Daily Operation
Raygene (688217.SH): The company did not repurchase shares in October.
On November 4th, Raytheon Genomics (688217.SH) announced that in October 2024, the company did not repurchase any shares. As of October 31, 2024, the company has repurchased a total of 669,621 shares through the Shanghai Stock Exchange trading system by means of centralized bidding trading method, accounting for 1.20% of the company's total share capital of 55,855,896 shares. The highest price for repurchase transactions was 27.67 yuan per share, the lowest price was 22.37 yuan per share, and the total amount paid was RMB 17,021,747.99 (excluding stamp duty, trading commissions, and other transaction fees).
Rayon Genomics 2024 Third Quarter Report
